)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MedCap
MedCap (MCAP) investor relations material
MedCap Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary23 Oct, 2026
Executive summary
Q3 net sales rose 13% to SEK 566.7m, including 5% organic growth; adjusted EBITA increased 30% to SEK 118.3m, with growth across all three business areas.
9M net sales grew 14% to SEK 1,729.6m and adjusted EBITA rose 29% to SEK 352.4m, supported by acquisitions and organic growth.
LTM revenue was SEK 2,321m; the snapshot reports a 20% LTM EBITA margin and 28% five-year EBITA CAGR.
Financial highlights
Q3 EBITDA was SEK 173.1m vs SEK 106.9m; EBITA was SEK 154.7m vs SEK 90.1m, including a SEK 36.4m positive XGX contingent-consideration remeasurement.
Q3 EBIT was SEK 127.1m vs SEK 71.5m; profit after tax was SEK 84.8m vs SEK 51.3m. Basic EPS was SEK 5.7 vs SEK 3.4; adjusted EPS was SEK 2.3 vs SEK 3.6.
9M EBITDA was SEK 447.7m vs SEK 315.8m; EBIT was SEK 312.0m vs SEK 213.9m; profit after tax was SEK 209.8m vs SEK 155.7m.
9M operating cash flow increased to SEK 270.1m from SEK 191.2m; working capital absorbed cash as receivables and inventory increased.
Outlook and guidance
Financial objectives: annual EBITA growth CAGR above 15%, return on equity above 20% and net debt/EBITDA below 3x.
Acquisition discussions remain relatively high and prospects for further acquisitions are considered favourable; a strong balance sheet and low leverage support acquisition capacity.
Specialty Pharma’s margin is expected to strengthen as new launches and existing products entering additional markets contribute a larger share of sales.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MedCap
- FY sales grew 43% and adjusted EBITDA 45%, with growth across all business areas.MCAP
Q4 2023 - Q2 2026 net sales up 16% and EBITA up 28%, with strong margins and active acquisitions.MCAPQ2 2026
- Adjusted EBITA rose 30% on 13% higher sales, with strong growth across all segments.MCAPQ1 2026
- Q4 2025 delivered 25% sales growth, 68% EBITA growth, and robust margins across all segments.MCAPQ4 2025
- Strong growth in life science through buy & build, with 19% sales and 29% EBITA CAGR.MCAPCompany presentation
- Strong revenue growth and strategic acquisitions drive expansion in life science markets.MCAPAGM 2025 presentation
- Achieved SEK 1,807 million revenue in 2024 with a 23% EBITA CAGR, driven by acquisitions.MCAPCompany presentation
- Life science group achieves robust growth via acquisitions and innovation in core business areas.MCAPSEB Nordic Seminar presentation
- Sales up 14% in 2024, but Specialty Pharma weakness weighed on EBITA.MCAPQ4 2024
Next MedCap earnings date
Q4 20265 Feb, 2027
MedCap
Next MedCap earnings date
Q4 20265 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MedCap is a European investment company that primarily focuses on acquiring and developing well-run small and medium-sized life science companies. They operate and are primarily active in the areas of MedTech and Specialty Pharma, but also consider opportunities in other sub-sectors of the Life Science industry.